An interventional study of inulin and maltodextrin in Diet Modification and Overweight, sponsored by Max Planck Institute for Human Cognitive and Brain Sciences. Completed at 1 site in Germany. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-27.
Sponsored by Max Planck Institute for Human Cognitive and Brain Sciences · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 151 studies in Overweight with a site in Germany — 40 open to participants now, 62 under way, 34 of them phase 3. Overweight · Germany.
Among the 151 studies in Overweight with a site in Germany, this one is the 113th largest by enrollment of the 142 interventional ones that give a count, is one of 11 that started in 2019, is one of 53 with no phase, and was the 50th registered.
3,623 studies on the registry are indexed under Overweight; 864 are open to participants now.
Browse Overweight studies →40 of the 151 studies in Overweight with a site in Germany are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Germany, United States, Argentina and 8 more countries
Ages 18+
German Diabetes Center · Sites in Germany
Ages 19–75
Novo Nordisk A/S · Sites in Germany
Ages 18+
Boehringer Ingelheim · Sites in Germany
Ages 18–74
Buchinger Wilhelmi Development & Holding GmbH · Sites in Germany
Ages 18–65 · Healthy volunteers
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 538 Overweight studies recruiting now, 163 (30%) set no upper age limit and 348 (65%) stop at 75 or younger; 64 take children under 18; 206 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
151 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 10 · Phase 3 48 · Phase 4 6
First in 2004; this study’s year is marked. 11 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 61 is below the median of 78 across 3,142 interventional studies indexed under Overweight.
Median enrollment 131 across the 142 interventional studies, 300 across the 9 observational. Of the 81 that completed or were terminated, 13 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
97 of 151 have an industry lead sponsor. The 10 most frequent:
Max Planck Institute for Human Cognitive and Brain Sciences is the lead sponsor of 10 studies on the registry; 3 are open to participants now.
Max Planck Institute for Human Cognitive and Brain Sciences has 3 studies filed under Overweight — fewer than ten, so there is no comparison to draw.
24 of the studies in Overweight with a site in Germany that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
Add all 24 to your calendar (.ics) → With an account.
Among the 151 studies in Overweight with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The central research question aims to understand what drives individuals to make and maintain a vegan / vegetarian dietary decision, to investigate whether there are possible predictors that might influence such a decision and whether personality differences already exist or can only be measured after the change in diet. The investigators will examine the effects of a high-fiber diet on food wanting on a neural and on a behavioral level. The microbiome is suggested to mediate the expected changes in food wanting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dietary Supplement: inulin
Dietary Supplement: maltodextrin
prebiotic supplement
placebo supplement
fMRI BOLD activity during food wanting
Time frame: 14 days
microbial alpha and beta diversity
The taxonomic structure of the microbial community will be determined using 16S rRNA gene sequencing. The reads from the sequencing data will be assigned to taxa by sequence similarity using puplic available data bases. Relative distribution of microbial taxa is then based on the number of reads assigned to each taxa. For the description of the the community the alpha diversity of each sample will be determined based on species richness, evenness of species distribution which is combined in the single value of the Shannon diversity index. Furthermore beta-diversity, how the microbial communities differ between sample, will be analysed by principal component analysis as well as non-metric multidimensional scaling. In addition, for each taxa significant difference between sample groups will be assessed by comparing the relative number of reads.
Time frame: 14 days
fMRI BOLD activity memory performance
Time frame: 14 days
positive and negative affect
PANAS (Positive and Negative Affect Schedule); scores can range from 10 - 50, with higher (lower) scores representing higher (lower) levels of positive (negative) affect
Time frame: 14 days
mood
POMS (Profile of Mood States); four scales (Depression/Anxiety, Fatigue, Vigor, Anger), 35 items, 7 point scale, instruction "How you have been feeling during the past 24 hours?"
Time frame: 14 days
emotional health
BDI-II (Beck Depression Inventory); score minimum 0 to maximum 21
Time frame: 14 days
well-being
WHO-5 (World Health Organization Well-Being Index); measures life quality and life contentment; score minimum 0 to maximum 5 with higher score representing higher life quality and life contentment
Time frame: 14 days
satiety
self-reported hunger scale; visual analogue scale; score minimum 0 to maximum 8
Time frame: 14 days
serum lipid metabolism markers
total cholesterol, triglycerides, high density lipoprotein, low density lipoprotein
Time frame: 14 days
serum glucose metabolism markers
glucose, insulin
Time frame: 14 days
serum glucose metabolism markers
long-term glucose marker HbA1C
Time frame: 14 days
serum inflammatory markers
high sensitivity C-reactive protein, interleukin-6
Time frame: 14 days
hunger hormones
leptin, ghrelin, Glucagon-like peptide-1 (GLP-1), peptide YY
Time frame: 14 days
serum microbial metabolic markers
short-chain fatty acids (SCFA), trimethylamine N-oxide (TMAO), bile acids
Time frame: 14 days
personality traits
BFMM (BIG FIVE Mine Marker); measures the Big Five personality traits as states; 5 subscales (neuroticism, extraversion, openness, agreeableness, conscientiousness); higher scores means being more extreme for a certain state
Time frame: 14 days
gastrointestinal health
GQLI-10 (Gastrointestinal Quality of Life Index); 10 items to measure quality of life regarding gastrointestinal symptoms; the higher the score the stronger the symptoms
Time frame: 14 days
Ran from Jan 2019 to primary completion in Nov 2020, 22 months.
Of 1,314 non-industry interventional studies with no phase under Overweight, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 38. This study's 22 months is above that.
Counting every sponsor, half of 1,427 studies reached it within 17 months; a quarter within 7 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inulin
Max Planck Institute for Human Cognitive and Brain Sciences